Analysis of the assortment and economic availability of neuroprotectors at the pharmaceutical Market of ukraine
DOI:
https://doi.org/10.24959/cphj.14.1286Keywords:
pharmaceutical market analysis, medicines with neuroprotective action, economic availability, ischemic stroke attackAbstract
The article presents the results of analysis of the pharmaceutical market and economic availability of medicines with the neuroprotective action. Neuroprotection is one of the important directions of the differentiated pharmacotherapy during the acute period of the cerebral circulation impairment (ACCI). It has been found that the maximum achievable therapeutic effect of neuroprotectors could be obtained only in case of observan of three basic principles of evidence based medicine: to prescribe medicines, which efficiency has been proven in large randomized clinical trials or in meta-analyses; to start the treatment as soon as possible (during the first hours from the moment of the ischemic stroke attack); the appropriate efficiency of these medicines can be reached only at the background of the optimal level of the cerebral blood circulation. The volume of neuroprotectors consumption in Ukraine is rather high, and it leads to considerable expences for ACCI pharmacotherapy. At the modern pharmaceutical market of Ukraine medicines with the neuroprotective action used in the treatment of ACCI are widely provided by 26 International Nonproprietary Names (INN) in the form of 85 trade names (TN) produced in different countries of the world. The ratio of domestic and foreign medicines is 1:1.4. The prices of medicines vary in the broad range from 0,68 UAH to 4286,65 UAH, and it gives the opportunity to choose medicines considering their clinical efficacy and cost. Among the INN medicines with the neuroprotective action only 5 medicines (19%), namely glycine, GABA, piracetam combinations with cinnarizine and GABA, and vinpocetine proved to be the most available to consumers. It has been determined that the rate of prices elevation for the majority of the neuroprotectors analyzed are higher than the rate of the wage growth during the period studied. It raises a question of choosing the optimal neuroprotective medicines on the basis of the pharmacoeconomic assessment results.
References
Дедов И.И. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И.Дедова. – 5-е изд., 2011. [Электронный ресурс]. – Режим доступа: www.endocrincentr.ru/SD.
Колбин А.С. // Качественная клиническая практика. – 2011. – №1. – С. 92-96.
Морозов А.М., Яковлева Л.В., Бездітко Н.В. та ін. Методичні рекомендації з оцінки клінічної та економічної доцільності використання лікарських засобів у лікувально-профілактичному закладі (супровід формулярної системи). – К., 2012. – 59 с.
Наказ МОЗ України від 21.12.2012 № 1118 «Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при цукровому діабеті ІІ типу». [Электронный ресурс]. – Режим доступа: www.moz.gov.ua/ua/portal/dn_20121221_1118.htm.
Ametow A., Barinov A., O’brien P. et al. // Diabetes Care. – 2003. – Vol. 26. – P. 770-776.
Brandle M., Azoulay M., Greiner R. // Intern. J. of Clinical Pharmacol. and Therapeutics. – 2007. – Vol. 45. – P. 203-220.
Janka H.U. // Eur. J. Health Econ. – 2008. – Vol. 9 (2). – P. 165-170.
Ziengler D., Nowak H., Kempler I. et al. // Diabetic Medicine. – 2004. – Vol. 21. – P. 114-121.
Ziegler D., Movsesyan L., Mankovsky B. et al. // Diabetes Care. – 2009. – Vol. 32 (8). – Р. 1479-1484.
Downloads
Published
Issue
Section
License
Copyright (c) 2014 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
